These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28703335)

  • 41. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors.
    Takeda Y; Tsuta K; Shibuki Y; Hoshino T; Tochigi N; Maeshima AM; Asamura H; Sasajima Y; Ito T; Matsuno Y
    Arch Pathol Lab Med; 2008 Feb; 132(2):239-43. PubMed ID: 18251583
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mammaglobin-A immunohistochemistry in primary central nervous system neoplasms and intracranial metastatic breast carcinoma.
    Cimino PJ; Perrin RJ
    Appl Immunohistochem Mol Morphol; 2014 Jul; 22(6):442-8. PubMed ID: 23958549
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma.
    Han JH; Kang Y; Shin HC; Kim HS; Kang YM; Kim YB; Oh SY
    Arch Pathol Lab Med; 2003 Oct; 127(10):1330-4. PubMed ID: 14521461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytokeratin 7, GATA3, and SOX-10 is a Comprehensive Panel in Diagnosing Triple Negative Breast Cancer Brain Metastases.
    Statz E; Jorns JM
    Int J Surg Pathol; 2021 Aug; 29(5):470-474. PubMed ID: 33543662
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative Sensitivities and Specificities of Antibodies to Breast Markers GCDFP-15, Mammaglobin A, and Different Clones of Antibodies to GATA-3: A Study of 338 Tumors Using Whole Sections.
    Kandalaft PL; Simon RA; Isacson C; Gown AM
    Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):609-614. PubMed ID: 26447897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of GATA3 in breast carcinomas: a review.
    Asch-Kendrick R; Cimino-Mathews A
    Hum Pathol; 2016 Feb; 48():37-47. PubMed ID: 26772397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors.
    Chia SY; Thike AA; Cheok PY; Tan PH
    Breast; 2010 Oct; 19(5):355-9. PubMed ID: 20347310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preferential expression of NY-BR-1 and GATA-3 in male breast cancer.
    Biserni GB; Di Oto E; Moskovszky LE; Foschini MP; Varga Z
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):199-204. PubMed ID: 29116378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The diagnostic utility of trichorhinophalangeal syndrome type 1 immunohistochemistry for metastatic breast carcinoma in effusion cytology specimens.
    Chen CJ; Hang JF; Chen YA; Lin SJ; Chiu HM; Hsu CY; Lai CR; Yang CS
    Cancer Cytopathol; 2023 Apr; 131(4):226-233. PubMed ID: 36399408
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GATA binding protein 3 (GATA3) as a marker for metaplastic spindle cell carcinoma of the breast.
    Jin C; Hacking S; Sajjan S; Kamanda S; Bhuiya T; Nasim M
    Pathol Res Pract; 2021 May; 221():153413. PubMed ID: 33770555
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences in GATA3 expression among histological/molecular subtypes and grades in infiltrating breast carcinoma (IBC) are important in the diagnosis of metastatic breast carcinoma.
    Stolnicu S; Tunde C; Cadar A; Boros M
    Pol J Pathol; 2020; 71(1):62-65. PubMed ID: 32429656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology.
    Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U
    Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bone marrow mammaglobin-1 (SCGB2A2) immunohistochemistry expression as a breast cancer specific marker for early detection of bone marrow micrometastases.
    Talaat IM; Hachim MY; Hachim IY; Ibrahim RAE; Ahmed MAER; Tayel HY
    Sci Rep; 2020 Aug; 10(1):13061. PubMed ID: 32747636
    [TBL] [Abstract][Full Text] [Related]  

  • 54. GATA3 staining in primary cutaneous apocrine cribriform carcinoma: Usefulness to differentiate it from breast cancer metastasis.
    Llamas-Velasco M; Pérez-Gónzalez YC; Daudén E; Rütten A
    J Cutan Pathol; 2018 May; 45(5):348-351. PubMed ID: 29431200
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression Pattern of Smad4/GATA3 as a Predictor of Survival in Invasive Ductal Carcinoma of the Breast.
    Min KW; Kim DH; Do SI; Chae SW; Kim K; Sohn JH; Lee HJ; Do IG; Pyo JS; Kim Y; Kim DH; Yang JH; Lee SJ; Oh YH; Oh S; Choi SH; Park YL; Park CH; Kim EK; Kwon MJ; Seo J
    Pathobiology; 2017; 84(3):130-138. PubMed ID: 28288473
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Higher levels of GATA3 predict better survival in women with breast cancer.
    Yoon NK; Maresh EL; Shen D; Elshimali Y; Apple S; Horvath S; Mah V; Bose S; Chia D; Chang HR; Goodglick L
    Hum Pathol; 2010 Dec; 41(12):1794-801. PubMed ID: 21078439
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance.
    Lu S; Yakirevich E; Wang LJ; Resnick MB; Wang Y
    BMC Cancer; 2019 Nov; 19(1):1085. PubMed ID: 31718619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.
    Mehra R; Varambally S; Ding L; Shen R; Sabel MS; Ghosh D; Chinnaiyan AM; Kleer CG
    Cancer Res; 2005 Dec; 65(24):11259-64. PubMed ID: 16357129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of GATA3 Versus BRST2 for the Identification of Metastatic Breast Carcinoma in the Upper GI Tract: Which Performs Better?
    Salagean D; Streutker C; Faragalla H; Jakate K
    Appl Immunohistochem Mol Morphol; 2019 Aug; 27(7):501-507. PubMed ID: 29629946
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer.
    Huo L; Zhang J; Gilcrease MZ; Gong Y; Wu Y; Zhang H; Resetkova E; Hunt KK; Deavers MT
    Histopathology; 2013 Jan; 62(2):267-74. PubMed ID: 22963676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.